ArticleCureus2024
Prevalence of Microbiologically Confirmed Female Genital Tuberculosis in a Tertiary Care Hospital in Faridabad, Haryana, India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to determine the prevalence of microbiologically confirmed female genital tuberculosis (FGTB) infection in patients attending a tertiary care hospital in North India. MATERIALS AND
methodsA total of 623 endometrial biopsy samples were processed in the mycobacteriology laboratory from the outpatient and inpatient gynecology departments between May 2022 and February 2024. Ziehl-Neelsen (ZN) smear was performed on all samples. Each sample was subsequently subjected to cartridge-based nucleic acid amplification test (CBNAAT) Xpert
resultsOf the 623 endometrial biopsy samples tested, 17 (2.73%) samples were positive for MTB by CBNAAT Ultra. The disease was most commonly observed in the reproductive age group between 21 and 35 years. ZN smear and culture were negative for all the samples received for endometrial TB. Of these 17 positive samples, one (5.9 %) was MTB detected (medium), four (23.5 %) (low), two (11.8 %) (very low), and 10 (58.8 %) (trace). RIF resistance was detected in one (5.9 %) of these 17 samples. However, the 10 samples that were detected as MTB trace and RIF indeterminate ideally need to be processed further by culture or by line probe assay to determine the drug resistance.
conclusionGenital TB is characterized by a low bacterial load. Therefore, a highly sensitive and specific molecular test is essential for confirming the diagnosis microbiologically. Our study found that Xpert MTB/RIF Ultra is particularly valuable because it detected 58.8% of cases as "TRACE," which might be missed by other testing methods. Early diagnosis using this test can significantly impact patient management, especially in cases related to infertility. This study effectively highlights the role of GeneXpert Ultra in documenting extra-pulmonary TB, including genital TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.